Wall Street analysts forecast that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report $340,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Redhill Biopharma’s earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $170,000.00. The firm is expected to report its next quarterly earnings results on Tuesday, July 25th.

According to Zacks, analysts expect that Redhill Biopharma will report full-year sales of $340,000.00 for the current year, with estimates ranging from $1.12 million to $3.75 million. For the next financial year, analysts expect that the firm will report sales of $45.54 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.14.

Several research analysts have commented on RDHL shares. FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a report on Wednesday, April 5th. Roth Capital set a $26.00 target price on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Thursday, May 4th. Finally, HC Wainwright set a $33.00 target price on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Thursday, May 4th.

Several hedge funds have recently bought and sold shares of RDHL. Bank of New York Mellon Corp bought a new stake in Redhill Biopharma during the first quarter valued at approximately $101,000. Family Management Corp bought a new stake in Redhill Biopharma during the first quarter valued at approximately $163,000. Penserra Capital Management LLC boosted its stake in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 6,172 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Redhill Biopharma during the fourth quarter valued at approximately $266,000. Institutional investors and hedge funds own 12.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/18/340000-00-in-sales-expected-for-redhill-biopharma-ltd-rdhl-this-quarter.html.

Redhill Biopharma (NASDAQ RDHL) opened at 8.60 on Friday. Redhill Biopharma has a 52 week low of $8.40 and a 52 week high of $16.54. The company’s 50 day moving average is $9.63 and its 200 day moving average is $10.04. The stock’s market cap is $146.26 million.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company. The Company is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs for the treatment of gastrointestinal (GI) and inflammatory diseases and cancer. Its seven clinical-stage therapeutic candidates include RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA, MESUPRON and RIZAPORT and related research and development programs.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.